Moonlake Immunotherapeutics (MLTX) PT Lowered to $20 at Guggenheim, removed as Best Idea
Tweet Send to a Friend
(Updated - September 30, 2025 6:42 AM EDT)
Guggenheim analyst Yatin Suneja lowered the price target on Moonlake Immunotherapeutics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Guggenheim analyst Yatin Suneja lowered the price target on Moonlake Immunotherapeutics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
